clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-12-865-872clinmed-1332Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНейросаркоидозNeurosarcoidosisТерпигоревС. А.TerpigorevS. A.

Станислав Анатольевич Терпигорев — д-р мед. наук, заведующий кафедрой внутренних болезней

Москва 

Stanislav A. Terpigorev — Doctor of Medical Sciences, Head of the Department of Internal Medicine

Moscow 

smith42@yandex.ruБогдановР. Р.BogdanovR. R.

Ринат Равилевич Богданов — д-р мед. наук, доцент, заведующий кафедрой неврологии 

Москва

Rinat R. Bogdanov — Candidate of Medical Sciences, Associate Professor, Head of the Department of Neurology

Moscow 

ДимерцевА. В.DimertsevA. V.

Алексей Владимирович Димерцев — канд. мед. наук, врач отделения нейрохирургии

Москва

Alexey V. Dimertsev — Candidate of Medical Sciences, Neurosurgeon, Department of Neurosurgery

Moscow 

ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, Институт усовершенствования врачейРоссияNational Medical and Surgical Center named after N.I. Pirogov of the Ministry of Healthcare of the Russia, Institute of Advanced Medical Training of DoctorsRussian Federation20250303202610312865872Copyright © Терпигорев С.А., Богданов Р.Р., Димерцев А.В., 20262026Терпигорев С.А., Богданов Р.Р., Димерцев А.В.Terpigorev S.A., Bogdanov R.R., Dimertsev A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1332

Нейросаркоидоз — редкое проявление системного саркоидоза, характеризующееся поражением центральной и периферической нервной системы. Клиническая картина отличается высокой вариабельностью и зависит от локализации гранулематозного воспаления, что затрудняет диагностику. В статье рассмотрены современные представления о патогенезе, клинических фенотипах и дифференциальной диагностике нейросаркоидоза. Описаны методы нейровизуализации, лабораторной диагностики и морфологической верификации заболевания. Особое внимание уделено терапевтическим стратегиям, включая глюкокортикостероидную и иммуносупрессивную терапию. Обсуждаются вопросы прогноза и возможные направления дальнейших исследований.

Neurosarcoidosis is a rare manifestation of systemic sarcoidosis characterized by involvement of both the central and peripheral nervous systems. The clinical presentation is highly variable and depends on the localization of granulomatous inflammation, which complicates the diagnostic process. This article reviews current understanding of the pathogenesis, clinical phenotypes, and differential diagnosis of neurosarcoidosis. It also describes methods of neuroimaging, laboratory diagnostics, and histological verification of the disease. Special attention is given to therapeutic strategies, including glucocorticoid and immunosuppressive therapy. Prognostic considerations and potential directions for future research are discussed.

нейросаркоидозсаркоидозгранулематоздифференциальный диагнознейровизуализацияneurosarcoidosissarcoidosisgranulomatosisdifferential diagnosisneuroimagingReferencesStatement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 1999;160(2):736–55.Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 1999;160(2):736–55.Stern B., Royal W 3rd., Gelfand J., Clifford D., Tavee J., Pawate S. et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–1553.Stern B., Royal W 3rd., Gelfand J., Clifford D., Tavee J., Pawate S. et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546–1553.Fritz D., van de Beek D., Brouwer M. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurology. 2016;16(1):220.Fritz D., van de Beek D., Brouwer M. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurology. 2016;16(1):220.Kidd D.P. “Neurosarcoidosis: clinical manifestations, investigation and treatment”. Practical Neurology. 2020;20(3):199-212.Kidd D.P. “Neurosarcoidosis: clinical manifestations, investigation and treatment”. Practical Neurology. 2020;20(3):199-212.Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Баранова О.П., Борисов С.Е., Геппе Н.А. и др. Саркоидоз: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(6):806–833.Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Baranova O.P., Borisov S.E., Geppe N.A. et al. Sarcoidosis: federal clinical guidelines for diagnosis and treatment. Pulmonology. 2022;32(6):806–833. (In Russian).Stern B., Krumholz A., Johns C., Scott P., Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–917. DOI: 10.1001/archneur.1985.04060080095022Stern B., Krumholz A., Johns C., Scott P., Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–917. DOI: 10.1001/archneur.1985.04060080095022Berker T. K., Isikay A., Gurlek A. A. Panhypopituitarism as the first manifestation of sarcoidosis: case report and review of the literature. Pituitary. 2004;7(2):73 –78.Berker T. K., Isikay A., Gurlek A. A. Panhypopituitarism as the first manifestation of sarcoidosis: case report and review of the literature. Pituitary. 2004;7(2):73 –78.Tavee J.O., Karwa K., Ahmed Z., Thompson N., Parambil J., Culver D.A. Sarcoidosis- associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir. Med. 2017;126:135–138.Tavee J.O., Karwa K., Ahmed Z., Thompson N., Parambil J., Culver D.A. Sarcoidosis- associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir. Med. 2017;126:135–138.Ginat D.T., Dhillon G., Almast J. Magnetic resonance imaging of neurosarcoidosis. J. Clin. Imaging Sci. 2011;1:15. DOI: 10.4103/2156-7514.76693. PMID: 21977388; PMCID: PMC3173834Ginat D.T., Dhillon G., Almast J. Magnetic resonance imaging of neurosarcoidosis. J. Clin. Imaging Sci. 2011;1:15. DOI: 10.4103/2156-7514.76693. PMID: 21977388; PMCID: PMC3173834Imsirovic B., Guso E., Omerhodzic I., Tawil AA., Merhemic Z. Neurosarcoidosis — the Role of Magnetic Resonance Imaging in Diagnostics. Acta Inform. Med. 2023;31(1):73–75. DOI: 10.5455/aim.2023.31.73-75. PMID: 37038484; PMCID: PMC10082661Imsirovic B., Guso E., Omerhodzic I., Tawil AA., Merhemic Z. Neurosarcoidosis — the Role of Magnetic Resonance Imaging in Diagnostics. Acta Inform. Med. 2023;31(1):73–75. DOI: 10.5455/aim.2023.31.73-75. PMID: 37038484; PMCID: PMC10082661Perillo T.; Capasso R.; Pinto A. Neuroimaging of the Most Common Meningitis and Encephalitis of Adults: A Narrative Review. Diagnostics. 2024;14:1064. DOI: 10.3390/diagnostics14111064Perillo T.; Capasso R.; Pinto A. Neuroimaging of the Most Common Meningitis and Encephalitis of Adults: A Narrative Review. Diagnostics. 2024;14:1064. DOI: 10.3390/diagnostics14111064Flanagan E.P., Kaufmann T.J., Krecke K.N. et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann. Neurol. 2016;79:437.Flanagan E.P., Kaufmann T.J., Krecke K.N. et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann. Neurol. 2016;79:437.Zajicek J.P., Scolding N.J., Foster O. et al. Central nervous system sarcoidosis — diagnosis and management. QJM. 1999;92:103.Zajicek J.P., Scolding N.J., Foster O. et al. Central nervous system sarcoidosis — diagnosis and management. QJM. 1999;92:103.Murphy O.C., Salazar-Camelo A., Jimenez J.A., et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(4).Murphy O.C., Salazar-Camelo A., Jimenez J.A., et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(4).Petereit HF, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J. Neurol. 2010; 257:1855.Petereit HF, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J. Neurol. 2010; 257:1855.Stewar R.D., Auffret M.D., Warr A., Wiser A.H. et al. Assembly of 913 microbial genomes from metagenomic sequencing of the cow rumen. Nature Communications. 2018;9(1):870.Stewar R.D., Auffret M.D., Warr A., Wiser A.H. et al. Assembly of 913 microbial genomes from metagenomic sequencing of the cow rumen. Nature Communications. 2018;9(1):870.Bilgin Topçuoğlu, Özgür & Kavas, Murat & O ztas, S. & Nc, Saeedudheen & Cetintas Afsar, Gulgun & Saraç, Sema & Midi, Ipek. (2016). EEG in Sarcoidosis Patients Without Neurological Findings. Clinical EEG and Neuroscience. 48(1). DOI: 10.1177/1550059416646651Bilgin Topçuoğlu, Özgür & Kavas, Murat & O ztas, S. & Nc, Saeedudheen & Cetintas Afsar, Gulgun & Saraç, Sema & Midi, Ipek. (2016). EEG in Sarcoidosis Patients Without Neurological Findings. Clinical EEG and Neuroscience. 48(1). DOI: 10.1177/1550059416646651Bradshaw MJ., Pawate S., Koth LL., Cho TA., Gelfand JM. Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment. Neurol. Neuroimmunol. Neuroinflamm. 2021;8(6):e1084.Bradshaw MJ., Pawate S., Koth LL., Cho TA., Gelfand JM. Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment. Neurol. Neuroimmunol. Neuroinflamm. 2021;8(6):e1084.Dudesek A., Rimmele F., Tesar S., Kolbaske S., Rommer PS., Benecke R., Zettl UK. CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders. Clin. Exp. Immunol. 2014;175(3):385–396. DOI: 10.1111/cei.12204. PMID: 24028073; PMCID: PMC3927899Dudesek A., Rimmele F., Tesar S., Kolbaske S., Rommer PS., Benecke R., Zettl UK. CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders. Clin. Exp. Immunol. 2014;175(3):385–396. DOI: 10.1111/cei.12204. PMID: 24028073; PMCID: PMC3927899Salvarani C, Brown R.D. Jr, Calamia K.T. et al. Primary CNS vasculitis with spinal cord involvement. Neurology. 2008;70:2394.Salvarani C, Brown R.D. Jr, Calamia K.T. et al. Primary CNS vasculitis with spinal cord involvement. Neurology. 2008;70:2394.Скрипченко Н.В., Лобзин Ю.В., Иванова Г.П., Команцев В.Н., Алексеева Л.А., Иванова М.В., Вильниц А.А., Горелик Е.Ю., Скрипченко Е.Ю. Нейроинфекции у детей. Детские инфекции. 2014;13(1):8–18.Skripchenko N.V., Lobzin Yu.V., Ivanova G.P., Komantsev V.N., Alekseeva L.A., Ivanova M.V., Solnits A.A., Gorelik E.Yu., Skripchenko E.Yu. Neuroinfections in children. Childhood infections. 2014;13(1):8–18. (In Russian).Tunkel A. R., Glaser C. A., Bloch K. C., Sejvar et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2008;47(3):303–327.Tunkel A. R., Glaser C. A., Bloch K. C., Sejvar et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2008;47(3):303–327.Barney J. Stern, Walter Royal III, Jeffrey M. Gelfand, MD, David B. Clifford, et al. JAMA Neurol. 2018;75(12):1546–1553. DOI: 10.1001/jamaneurol.2018.2295 Published online August 27, 2018.Barney J. Stern, Walter Royal III, Jeffrey M. Gelfand, MD, David B. Clifford, et al. JAMA Neurol. 2018;75(12):1546–1553. DOI: 10.1001/jamaneurol.2018.2295 Published online August 27, 2018.Sobic-Saranovic D., Grozdic I., Videnovic-Ivanov J., Artiko V., Petrovic S., Saranovic D. et al. The clinical impact of 18F-FDG PET and PET/CT in patients with sarcoidosis. Journal of Nuclear Medicine. 2012;53(9):1543–1550Sobic-Saranovic D., Grozdic I., Videnovic-Ivanov J., Artiko V., Petrovic S., Saranovic D. et al. The clinical impact of 18F-FDG PET and PET/CT in patients with sarcoidosis. Journal of Nuclear Medicine. 2012;53(9):1543–1550Baughman R.P., Valeyre D., Korsten P., Mathioudakis A.G., Wuyts W.A., Wells A., et al., ERS clinical practice guidelines on treatment of sarcoidosis, Eur. Respir. J. 2021. DOI: 10.1183/13993003.04079-2020. PubMed PMID: 34140301Baughman R.P., Valeyre D., Korsten P., Mathioudakis A.G., Wuyts W.A., Wells A., et al., ERS clinical practice guidelines on treatment of sarcoidosis, Eur. Respir. J. 2021. DOI: 10.1183/13993003.04079-2020. PubMed PMID: 34140301Paramothayan N.S., Lasserson T.J., Jones P.W. Corticosteroids for pulmonary sarcoidosis. Epub 2005/04/23, Cochrane Database Syst. Rev. 2 (2005) CD001114, DOI: 10.1002/14651858.CD001114.pub2. PubMed PMID: 15846612; PubMed Central PMCID: PMCPMC6464973.Paramothayan N.S., Lasserson T.J., Jones P.W. Corticosteroids for pulmonary sarcoidosis. Epub 2005/04/23, Cochrane Database Syst. Rev. 2 (2005) CD001114, DOI: 10.1002/14651858.CD001114.pub2. PubMed PMID: 15846612; PubMed Central PMCID: PMCPMC6464973.Rahaghi F.F., Baughman R.P., Saketkoo L.A., Sweiss N.J., Barney J.B., Birring S.S., et al., Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur. Respir. Rev. 2020;29(155):190146. DOI: 10.1183/16000617.0146-2019Rahaghi F.F., Baughman R.P., Saketkoo L.A., Sweiss N.J., Barney J.B., Birring S.S., et al., Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur. Respir. Rev. 2020;29(155):190146. DOI: 10.1183/16000617.0146-2019Murayama K., Inoue A., Nakamura Y., Ochi M., Shigekawa S., Watanabe H., Kitazawa R., Kunieda T. A rare case of neurosarcoidosis occurred only in the medulla oblongata mimicking malignant brain tumor. Surgical neurology international. 2021;12:243.Murayama K., Inoue A., Nakamura Y., Ochi M., Shigekawa S., Watanabe H., Kitazawa R., Kunieda T. A rare case of neurosarcoidosis occurred only in the medulla oblongata mimicking malignant brain tumor. Surgical neurology international. 2021;12:243.Shields R., Sagan O., Roebke L., Vander Maten J., Shah S., Chang G., Ibrahim D., Naz S. Rare case of multifocal extradural and intramedullary neurosarcoidosis without pulmonary involvement: a case report and literature review. Spinal cord series and cases. 2021;7(1):89.Shields R., Sagan O., Roebke L., Vander Maten J., Shah S., Chang G., Ibrahim D., Naz S. Rare case of multifocal extradural and intramedullary neurosarcoidosis without pulmonary involvement: a case report and literature review. Spinal cord series and cases. 2021;7(1):89.Johns C., Johns C. A case of central diabetes insipidus secondary to neurosarcoidosis. Cureus. 2020;12(10):e11119. DOI: 10.7759/cureus.11119. PMID: 33240714; PMCID: PMC7682679)Johns C., Johns C. A case of central diabetes insipidus secondary to neurosarcoidosis. Cureus. 2020;12(10):e11119. DOI: 10.7759/cureus.11119. PMID: 33240714; PMCID: PMC7682679)Sponsler J., Werz M., Maciunas R., Cohen M. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: case reports and review of the literature. Epilepsy Behav. 2005;6(4):623– 30. DOI: 10.1016/j.yebeh.2005.02.016. PMID: 15907759)Sponsler J., Werz M., Maciunas R., Cohen M. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: case reports and review of the literature. Epilepsy Behav. 2005;6(4):623– 30. DOI: 10.1016/j.yebeh.2005.02.016. PMID: 15907759)Pandey A., Stoker T., Adamczyk L. A., & Stacpoole S. (2021). Aseptic meningitis and hydrocephalus secondary to neurosarcoidosis. BMJ case reports. 2021;14(8):e242312.Pandey A., Stoker T., Adamczyk L. A., & Stacpoole S. (2021). Aseptic meningitis and hydrocephalus secondary to neurosarcoidosis. BMJ case reports. 2021;14(8):e242312.Joubert B., Chapelon-Abric C., Biard L. et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol. 2017;74:1336–1344.Joubert B., Chapelon-Abric C., Biard L. et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol. 2017;74:1336–1344.Affan M., Mahajan A., Rehman T. et al. The effect of race on clinical presentation and outcomes in neurosarcoidosis. J. Neurol. Sci. 2020;417:117073.Affan M., Mahajan A., Rehman T. et al. The effect of race on clinical presentation and outcomes in neurosarcoidosis. J. Neurol. Sci. 2020;417:117073.Thillai M., Atkins C.P., Crawshaw A., Hart S.P., Ho L.P., Kouranos V. et al. BTS Clinical Statement on pulmonary sarcoidosis, Thorax. 2021;76(1) :4–20, DOI: 10.1136/thoraxjnl-2019-214348. PubMed PMID: 33268456Thillai M., Atkins C.P., Crawshaw A., Hart S.P., Ho L.P., Kouranos V. et al. BTS Clinical Statement on pulmonary sarcoidosis, Thorax. 2021;76(1) :4–20, DOI: 10.1136/thoraxjnl-2019-214348. PubMed PMID: 33268456Pawate S., Moses H., Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102:449.Pawate S., Moses H., Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102:449.

The authors declare that there are no conflicts of interest present.